Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKCAOTCMKTS:BLUSFNASDAQ:CNSTOTCMKTS:CYDYNASDAQ:YMAB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/ABLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ACYDYCytoDyn$0.15$0.17$0.13▼$0.42$147.44M0.161.30 million shs420,675 shsYMABY-mAbs Therapeutics$14.84-2.9%$15.79$4.60▼$20.90$669.35M0.74341,731 shs365,385 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%BLUSFBELLUS Health0.00%0.00%0.00%0.00%+1.87%CNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CYDYCytoDyn-1.68%-3.22%-11.52%-9.46%-48.48%YMABY-mAbs Therapeutics-2.94%-1.07%-5.48%+31.68%+160.81%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AN/AN/AN/AYMABY-mAbs Therapeutics1.0368 of 5 stars2.21.00.00.01.74.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea TherapeuticsN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AYMABY-mAbs Therapeutics2.33Hold$16.5711.67% UpsideCurrent Analyst RatingsLatest CNST, YMAB, BLUSF, CYDY, and AKCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.003/4/2024YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/4/2024YMABY-mAbs TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.002/20/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $21.002/12/2024YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $18.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14BLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/ACYDYCytoDyn$270K536.89N/AN/A($0.12) per share-1.22YMABY-mAbs Therapeutics$84.82M7.66N/AN/A$2.32 per share6.40Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/ABLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/ACYDYCytoDyn-$79.82M-$0.05N/A∞N/AN/AN/A-478.47%N/AYMABY-mAbs Therapeutics-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)Latest CNST, YMAB, BLUSF, CYDY, and AKCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q3 2024CYDYCytoDynN/A-$0.01-$0.01-$0.01N/AN/A2/29/2024Q4 2023YMABY-mAbs Therapeutics-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78BLUSFBELLUS HealthN/A13.8713.87CNSTConstellation PharmaceuticalsN/A15.3915.39CYDYCytoDynN/A0.080.08YMABY-mAbs TherapeuticsN/A5.525.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%BLUSFBELLUS HealthN/ACNSTConstellation PharmaceuticalsN/ACYDYCytoDyn5.06%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%BLUSFBELLUS Health24.17%CNSTConstellation Pharmaceuticals43.70%CYDYCytoDyn0.71%YMABY-mAbs Therapeutics21.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableCYDYCytoDyn12992.87 million985.82 millionNot OptionableYMABY-mAbs Therapeutics10043.78 million34.37 millionOptionableCNST, YMAB, BLUSF, CYDY, and AKCA HeadlinesSourceHeadlineY-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024globenewswire.com - April 26 at 7:05 AMY-mAbs to Present at 2024 ASCO Annual Meetingglobenewswire.com - April 25 at 4:05 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%marketbeat.com - April 23 at 4:47 PMNew Strong Buy Stocks for April 19thzacks.com - April 19 at 7:50 AMY-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%finance.yahoo.com - April 18 at 1:21 PMNew Strong Buy Stocks for April 17thzacks.com - April 17 at 8:30 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%marketbeat.com - April 11 at 11:58 AMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analystsmarketbeat.com - April 10 at 2:30 AMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3% marketbeat.com - April 9 at 11:46 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%marketbeat.com - April 3 at 3:27 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19marketbeat.com - April 2 at 11:19 AMY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%marketbeat.com - April 1 at 2:01 PMDenali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)marketbeat.com - April 1 at 6:12 AMWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Betzacks.com - March 28 at 10:56 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%marketbeat.com - March 26 at 12:38 PMYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?zacks.com - March 20 at 8:40 AMY-mAbs Therapeutics Finance Chief Bo Kruse Resignsmarketwatch.com - March 15 at 8:31 AMY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officerfinanznachrichten.de - March 14 at 2:58 PMY-mAbs Therapeutics CFO Bo Kruse To Retiremarkets.businessinsider.com - March 14 at 9:57 AMY-mAbs Therapeutics Announces Resignation of Chief Financial Officerglobenewswire.com - March 14 at 9:05 AMWall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?zacks.com - March 12 at 10:55 AMBAMF, Corewell Health partner on clinical trial for advanced cancer treatmentcrainsgrandrapids.com - March 11 at 3:17 PMCracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeuticsmarkets.businessinsider.com - March 6 at 6:21 PMAre You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choicezacks.com - March 5 at 1:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.BELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Constellation PharmaceuticalsNASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.CytoDynOTCMKTS:CYDYCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Y-mAbs TherapeuticsNASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.